Veradermics, Incorporated (MANE) Stock Price & How to Invest

Veradermics, Inc. (NYSE: MANE) is a New Haven, Connecticut biopharmaceutical company founded in 2019 and focused on dermatology and aesthetics. Its lead candidate, VDPHL01, is a proprietary oral, extended-release formulation of minoxidil designed to boost hair regrowth while limiting the cardiac exposure associated with existing oral minoxidil use. The company has completed enrollment in a roughly 519-patient Phase 2/3 study for male pattern hair loss that showed statistically significant hair-count gains versus placebo, and has additional pivotal work underway. A smaller pipeline includes VDMN (a dissolvable microarray patch for common warts), VDAA (alopecia areata), and VDMC (molluscum contagiosum).

The investment picture is defined by the fact that Veradermics has no approved product and effectively no product revenue. After a February 2026 IPO at $17 and a follow-on plus private placement in April 2026, the company raised roughly $766 million in aggregate during 2026, giving it a substantial cash cushion to fund trials. The stock has been extraordinarily volatile, trading in a wide range and carrying a multibillion-dollar market value entirely on clinical expectations. As with any pre-revenue biotech, the range of outcomes is very wide, and the eventual result depends on trial data, FDA decisions, commercial execution, and competition.

Veradermics is pre-revenue and has no approved product, so it generates ongoing net losses (about $99 million on a trailing basis) and depends on clinical and regulatory success it has not yet achieved. The valuation, a multibillion-dollar market cap on essentially zero revenue, leaves little room for disappointment, and the shares have been extremely volatile since the IPO. Value is concentrated in VDPHL01, meaning a failed pivotal trial, a safety signal, or an FDA setback could sharply impair the company. Even with approval, it would compete against cheap generic minoxidil and finasteride and against telehealth platforms like Hims & Hers, Keeps, and Ro. Future capital raises could dilute existing shareholders.

6 analysts publish price targets on MANE, averaging $163.50 against a $105.00 price as of August 2026, or +55.7%. The published targets run from $135.00 to $182.00, a narrow spread, and the ratings split 7 buy, 0 hold, 0 sell. Over the last six months there have been 5 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full MANE forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Veradermics, Incorporated. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Large, underserved hair-loss market. Pattern hair loss affects a very large population, and existing options are dominated by decades-old generics (topical minoxidil, oral finasteride) and cash-pay telehealth. The most optimistic published target, $182.00, assumes this works close to its best case.

The case against. Veradermics is pre-revenue and has no approved product, so it generates ongoing net losses (about $99 million on a trailing basis) and depends on clinical and regulatory success it has not yet achieved. The most pessimistic target, $135.00, is roughly what MANE is worth if this bites instead.

Read the full bull and bear case on MANE, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Veradermics, Incorporated's investor relations page or your broker.

• Revenue (TTM): ~$0 (pre-commercial)
• Net loss (TTM): ~$99M
• EPS (TTM): ~-$15.84
• Cash & securities: ~$391M at Mar 31, 2026 (pre later raise)
• Market cap: ~$4.4B
• Shares outstanding: ~42M

Traditional valuation multiples do not apply because Veradermics has no product revenue and posts consistent losses. The market value reflects expectations for VDPHL01 rather than current financials. The stock has swung across a wide 52-week range (roughly $32 to $131) since its February 2026 IPO at $17.

Other names that sit close to MANE: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get MANE exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so MANE sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where MANE fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

MANE is a richly valued, pre-commercial biotech whose value hinges almost entirely on whether VDPHL01 reaches the market, which makes it a high-volatility, binary-outcome holding.

Whether MANE is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is MANE a buy or a sell?, and where the stock could go from here in the MANE stock forecast.

For income investors, whether MANE pays a dividend and how the payout looks is covered in does MANE pay a dividend? And to weigh MANE against a peer, read the full side-by-side comparisons: MANE vs HIMS and MANE vs MRNA.